Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

about

Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT.

P2860

Q33746730-0E1A1A4A-2E15-4D44-AE6A-08DD7417FA63

P2860

Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

Item

http://www.wikidata.org/entity/Q50448290

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Impact of ABO blood group mism ...... onditioned haematopoietic SCT.

@en

Impact of ABO blood group mism ...... onditioned haematopoietic SCT.

@nl

type

Item

label

Impact of ABO blood group mism ...... onditioned haematopoietic SCT.

@en

Impact of ABO blood group mism ...... onditioned haematopoietic SCT.

@nl

prefLabel

Impact of ABO blood group mism ...... onditioned haematopoietic SCT.

@en

Impact of ABO blood group mism ...... onditioned haematopoietic SCT.

@nl

P1476

Impact of ABO blood group mism ...... onditioned haematopoietic SCT.

@en

P2093

A Clark

http://www.w3.org/2001/XMLSchema#string

A J Peniket

http://www.w3.org/2001/XMLSchema#string

J Ward

http://www.w3.org/2001/XMLSchema#string

P Medd

http://www.w3.org/2001/XMLSchema#string

R Gregg

http://www.w3.org/2001/XMLSchema#string

R Malladi

http://www.w3.org/2001/XMLSchema#string

T J Littlewood

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.

Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.

Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.

Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.

Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation.

Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.

The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation.

Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source.

Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility.

P2888

bmt.2015.51

P304

931-938

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2015.51

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anne Parker

Charlotte K Brierley

P577

2015-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25867645

http://www.w3.org/2001/XMLSchema#string

Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

about

P2860

P2860

Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698